ID   NMB
AC   CVCL_2143
DR   BTO; BTO:0005872
DR   BioSample; SAMN03473470
DR   cancercelllines; CVCL_2143
DR   Cell_Model_Passport; SIDM01383
DR   Cosmic; 717422
DR   Cosmic; 848937
DR   Cosmic; 930073
DR   Cosmic; 1019940
DR   Cosmic; 1109119
DR   Cosmic; 1109368
DR   Cosmic; 1162001
DR   Cosmic; 1167991
DR   Cosmic; 1518072
DR   Cosmic; 1526639
DR   Cosmic; 1543774
DR   Cosmic; 2239465
DR   DepMap; ACH-001367
DR   DSMZ; ACC-657
DR   DSMZCellDive; ACC-657
DR   GEO; GSM692862
DR   GEO; GSM2371251
DR   GEO; GSM2394366
DR   Wikidata; Q54930830
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   PubMed=922665;
RX   PubMed=3000378;
RX   PubMed=6888561;
RX   PubMed=11550280;
RX   PubMed=15892104;
RX   PubMed=16822308;
RX   PubMed=18724359;
RX   PubMed=20655465;
RX   PubMed=22213050;
RX   PubMed=24466371;
RX   PubMed=28350380;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: ~40-50 hours (DSMZ=ACC-657).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): DepMap; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 9,13
ST   D18S51: 17
ST   D19S433: 11,13
ST   D21S11: 28,29
ST   D2S1338: 20,23
ST   D3S1358: 15,17
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 14
ST   FGA: 22,25
ST   Penta D: 5,11
ST   Penta E: 13,16
ST   TH01: 7,8
ST   TPOX: 7,9
ST   vWA: 17,18,20
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   10M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
//
RX   PubMed=922665; DOI=10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1;
RA   Brodeur G.M., Sekhon G., Goldstein M.N.;
RT   "Chromosomal aberrations in human neuroblastomas.";
RL   Cancer 40:2256-2263(1977).
//
RX   PubMed=3000378; DOI=10.1016/0006-291X(85)91841-8;
RA   Ard M.D., Goldstein M.N., Nash D.R., Gottlieb D.I.;
RT   "NMB: a human neuroblastoma cell line with specific opiate binding
RT   sites.";
RL   Biochem. Biophys. Res. Commun. 133:60-66(1985).
//
RX   PubMed=6888561; DOI=10.1038/305245a0;
RA   Schwab M., Alitalo K., Klempnauer K.-H., Varmus H.E., Bishop J.M.,
RA   Gilbert F., Brodeur G.M., Goldstein M.N., Trent J.M.;
RT   "Amplified DNA with limited homology to myc cellular oncogene is
RT   shared by human neuroblastoma cell lines and a neuroblastoma tumour.";
RL   Nature 305:245-248(1983).
//
RX   PubMed=11550280; DOI=10.1002/gcc.1174;
RA   Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B.,
RA   Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.;
RT   "Combined M-FISH and CGH analysis allows comprehensive description of
RT   genetic alterations in neuroblastoma cell lines.";
RL   Genes Chromosomes Cancer 32:126-135(2001).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
//
RX   PubMed=18724359; DOI=10.1038/nature07261;
RA   Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A.,
RA   Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P.,
RA   Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A.,
RA   Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M.,
RA   Maris J.M.;
RT   "Identification of ALK as a major familial neuroblastoma
RT   predisposition gene.";
RL   Nature 455:930-935(2008).
//
RX   PubMed=20655465; DOI=10.1016/j.cell.2010.06.004;
RA   Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N.,
RA   Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C.,
RA   Messiaen L.M., Versteeg R., Bernards R.;
RT   "NF1 is a tumor suppressor in neuroblastoma that determines retinoic
RT   acid response and disease outcome.";
RL   Cell 142:218-229(2010).
//
RX   PubMed=22213050; DOI=10.1002/ijc.27415;
RA   Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J.,
RA   Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.;
RT   "PEA15 impairs cell migration and correlates with clinical features
RT   predicting good prognosis in neuroblastoma.";
RL   Int. J. Cancer 131:1556-1568(2012).
//
RX   PubMed=24466371; DOI=10.1593/tlo.13544;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
//
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
//